ANI Pharmaceuticals (ANIP) Set to Announce Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP) is scheduled to be releasing its earnings data before the market opens on Friday, November 8th. Analysts expect ANI Pharmaceuticals to post earnings of $1.09 per share for the quarter. ANI Pharmaceuticals has set its FY24 guidance at $4.38-4.82 EPS and its FY 2024 guidance at 4.380-4.820 EPS.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The firm had revenue of $138.00 million for the quarter, compared to the consensus estimate of $129.09 million. During the same period in the prior year, the firm posted $1.06 earnings per share. The firm’s quarterly revenue was up 18.5% compared to the same quarter last year. On average, analysts expect ANI Pharmaceuticals to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP opened at $57.25 on Friday. The company’s fifty day moving average price is $59.27 and its 200 day moving average price is $61.88. ANI Pharmaceuticals has a 1 year low of $48.20 and a 1 year high of $70.81. The company has a market capitalization of $1.20 billion, a PE ratio of 48.92 and a beta of 0.71. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.07 and a current ratio of 3.97.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. HC Wainwright reaffirmed a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 price objective on the stock. Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. Finally, Raymond James increased their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.